The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The Effect of Deprenyl (Selegiline) on the Natural History of Parkinson's Disease
Abstract
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early Parkinson's disease was initiated to determine whether deprenyl (a selective monoamine oxidase B inhibitor) would delay the need for L-dopa therapy by slowing the progression of the disease. Fifty-four patients were randomly assigned to deprenyl (10 mg/day) or placebo treatment groups and followed until L-dopa therapy was indicated or until the patient had been in the study for 3 years. Analysis of Kaplan-Meier survival curves for each group showed that deprenyl delayed the need for L-dopa therapy; the average time until L-dopa was needed was 312.1 days for patients in the placebo group and 548.9 days for patients in the deprenyl group. Disease progression, as monitored by five different assessment scales, was slowed (by 40 to 83% per year) in the deprenyl group compared to placebo. Therefore, early deprenyl therapy delays the requirement for antiparkinsonian medication, possibly by slowing progression of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Self-citationMiller, R. G. (1981) · Cited by 3,336
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Heikkila, R. E., Manzino, L., Cabbat, F. S., & Duvoisin, R. C. (1984) · Nature · doi:10.1038/311467a0 · Cited by 1,010
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Parkinson’s Disease and Movement Disorders
(2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10587 · Cited by 798
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
Markey, S. P., Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Herkenham, M. A. (1984) · Nature · doi:10.1038/311464a0 · Cited by 786
Cited by
Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Self-citationThe oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 917
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines
Olanow, C. W., Watts, R. L., & Koller, W. C. (2001) · Neurology · doi:10.1212/wnl.56.suppl_5.s1 · Cited by 715
Inhibition of monoamine oxidase B in the brains of smokers
Fowler, J. S., Volkow, N. D., Wang, G.-J., Pappas, N., Logan, J., MacGregor, R., Alexoff, D., Shea, C., Schlyer, D., Wolf, A. P., et al. (1996) · Nature · doi:10.1038/379733a0 · Cited by 656
Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study
Rajput, A. H., Rozdilsky, B., & Rajput, A. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100031814 · Cited by 596
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
Sofic, E., Lange, K. W., Jellinger, K., & Riederer, P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90355-b · Cited by 590
Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists
Turski, L., Bressler, K., Jürgen Rettig, K., Löschmann, P.-A., & Wachtel, H. (1991) · Nature · doi:10.1038/349414a0 · Cited by 546
Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds
Tipton, K. F., & Singer, T. P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13610.x · Cited by 539
Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., & Hyman, C. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb08880.x · Cited by 460
Lindvall, O., Sawle, G., Widner, H., Rothwell, J. C., Björklund, A., Brooks, D., Brundin, P., Frackowiak, R., Marsden, C. D., Odin, P., et al. (1994) · Annals of Neurology · doi:10.1002/ana.410350208 · Cited by 451
Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
Finberg, J. P. M., & Rabey, J. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00340 · Cited by 432
Aosaki, T., Graybiel, A. M., & Kimura, M. (1994) · Science · doi:10.1126/science.8023166 · Cited by 427
Langston, J. W. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179006 · Cited by 424
Self-citationAn introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Leenders, K. L., Salmon, E. P., Tyrrell, P., Perani, D., Brooks, D. J., Sager, H., Jones, T., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120034007 · Cited by 376
Epidemiology of Parkinson’s disease
Alves, G., Forsaa, E. B., Pedersen, K. F., Dreetz Gjerstad, M., & Larsen, J. P. (2008) · Journal of Neurology · doi:10.1007/s00415-008-5004-3 · Cited by 363
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment
La Rue, A., Koehler, K., Wayne, S., Chiulli, S., Haaland, K., & Garry, P. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.1.20 · Cited by 340
Saura, J., Kettler, R., Da Prada, M., & Richards, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01977.1992 · Cited by 337
Oxidative stress and antioxidant therapy in Parkinson's disease
Ebadi, M., Srinivasan, S. K., & Baxi, M. D. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00029-1 · Cited by 336
The effect of deprenyl and levodopa on the progression of Parkinson's disease
Olanow, C. W., Hauser, R. A., Gauguster, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., & Esterlitz, J. (1995) · Annals of Neurology · doi:10.1002/ana.410380512 · Cited by 334
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340331 · Cited by 320
The possible role of iron in the etiopathology of parkinson's disease
Youdim, M. B. H., Ben‐Shachar, D., & Riederer, P. (1993) · Movement Disorders · doi:10.1002/mds.870080102 · Cited by 301
The association of incident dementia with mortality in PD
Levy, G., Tang, M.-X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., & Marder, K. (2002) · Neurology · doi:10.1212/01.wnl.0000036610.36834.e0 · Cited by 297
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Paterson, I. A., Juorio, A. V., & Boulton, A. A. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb05764.x · Cited by 256
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
de Bie, R. M. A., Clarke, C. E., Espay, A. J., Fox, S. H., & Lang, A. E. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30036-3 · Cited by 200
Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134
Translational neuroimaging: positron emission tomography studies of monoamine oxidase
Fowler, J. S., Logan, J., Volkow, N. D., & Wang, G.-J. (2005) · Molecular Imaging and Biology · doi:10.1007/s11307-005-0016-1 · Cited by 81
Shimazu, S., & Miklya, I. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.11.016 · Cited by 57
Metadata
- Authors
- Tetrud, J. W., & Langston, J. W.
- Venue
- Science
- Published
- 1989-08-04
- Volume
- 245
- Issue
- 4917
- Pages
- 519-522
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1987655773
- Cited by
- 638
- References
- 22
- FWCI
- 53.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.